We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Aegis Acquires Diagnovus

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Aegis Acquires Diagnovus"

Listen with
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Aegis Sciences Corporation announced the acquisition of Diagnovus LLC.

“The asset acquisition of Diagnovus allows Aegis to expand our healthcare laboratory testing services,” stated Aegis Founder, Chairman and CEO Dr. David L. Black. “The delivery of patient-specific genetic information to physicians will improve management of disease and prescribing of necessary medication.”

Diagnovus has developed multiple molecular diagnostic assays, including a buccal swab test which provides insight into an individual’s response to certain medications based on genetic structure. This valuable information may increase the quality of care by reducing the time required to find the optimal course of treatment.

“As a scientist and entrepreneur, I am proud to have our team join Aegis,” stated Diagnovus President and Co-Founder Dr. James Stover. “Aegis’ reputation and client base will allow us to offer our developed molecular diagnostic testing services to a much larger patient population.”